Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Other

Jannsen Pharmaceutica Bv

J Guy Breitenbucher

James Patrick Edwards

Cheryl A Grice

Barbara A Pio

Jianmei Wei

Steven P Meduna

Haripada Khatuya

Hui Cai

Wei Xiao

Darin J Gustin

Kevin L Tays

Natalie Anne Hawryluk

Mary Pat Beavers

Mark Seierstad

Jeffrey E Merit

Nicholas I Carruthers

John M Keith

Michael D Hack

Alec D Lebsack

Kelly J McClure

Bryan James Branstetter

Xiaobing Li

Alison L Chambers

Ronald L Wolin

Chandravadan R Shah

Richard Apodaca

Laura C McAtee

Liming Huang

Mark S Tichenor

Jason Christopher Rech

William Moore Jones

Frank Urban Axe

Kanaka Pattabiraman

Kristen L Arienti

Clark A Sehon

Jing Liu

Amy K Timmons

Laurent Gomez

Michael K Ameriks

Brett D Allison

Nigel P Shankley

Alice Lee

Terrance D Barrett

Magda F Morton

Frank U Axe

Neelakandha S Mani

Henricus Jacobus Maria Gijsen

Wenying Chai

Timothy W Lovenberg

Xiaohu Deng

Lars Karlsson

Robin L Thurmond

Alice Lee-Dutra

Danielle K Neff

Siquan Sun

Yin Gu

Mirko Zaja

Joan M Pierce

Mark J Sierestad

Didier Jean-Calude Berthelot

Kelly J Mcclure

Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

Tetrahydro-pyrimidoazepines as modulators of TRPV1

Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1

Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed. 

Ethylene diamine modulators of fatty acid hydrolase

Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. 

Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. 

Heterocyclic amides as modulators of TRPA1

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.

Substituted pyrazoles

Growing community of inventors

Escondido, CA, United States of America

J Guy Breitenbucher